止血镇痛胶囊治疗原发性痛经的临床观察

Clinical observation on the treatment of primary dysmenorrhea with Zhixue Zhentong Jiaonang

ES评分 0

DOI 10.12208/j.ijmd.20250043
刊名
International Journal of Medicine and Data
年,卷(期) 2025, 9(2)
作者
作者单位

武都区第一人民医院 甘肃陇南

摘要
目的 本研究旨在探讨止血镇痛胶囊对原发性痛经的治疗效果。方法 研究对象为自2023年5月至2024年2月在我院就医的原发性痛经受试者,共80例。采用摸球法随机分组,对照组(40例)接受布洛芬胶囊治疗,试验组(40例)接受止血镇痛胶囊联合布洛芬胶囊进行治疗,比较两组受试者治疗前后的临床疗效、数字评定量表、COX痛经症状量表和不良反应发生情况。结果 治疗前两组受试者的临床疗效、数字评定量表、COX痛经症状量表差异无统计学意义(P>0.05)。然而,经过治疗后,试验组受试者的临床疗效、数字评定量表、COX痛经症状量表均明显优于对照组(P<0.05),且无不良反应发生。结论 止血镇痛胶囊联合布洛芬胶囊在治疗原发性痛经方面具有良好效果。
Abstract
Objective This study aims to explore the therapeutic effect of Zhixue Zhentong Jiaonang on primary dysmenorrhea. Methods The patients were 80 patients with primary dysmenorrhea who received medical treatment in our hospital from May 2023 to February 2024. The patients were randomly grouped by the ball-drawing method. The control group (40 patients) received ibuprofen capsules for treatment, and the experimental group (40 patients) received Zhixue Zhentong Jiaonang combined with ibuprofen capsules for treatment. The clinical efficacy, Numerical rating Scale, COX dysmenorrhea Symptom Scale and the occurrence of adverse reactions of the two groups before and after treatment were compared. Results Before treatment, there was no statistically significant difference in the clinical efficacy, Numerical Rating Scale, COX dysmenorrhea Symptom Scale, and between the two groups of patients (P>0.05). However, after treatment, the clinical efficacy, Numerical Rating Scale, COX dysmenorrhea Symptom Scale, of the patients in the experimental group were significantly better than those in the control group (P<0.05), and no adverse reactions occurred. Conclusion The combination of Zhixue Zhentong Jiaonang and ibuprofen Capsules has a good effect in the treatment of primary dysmenorrhea.
关键词
止血镇痛胶囊;原发性痛经;临床疗效
KeyWord
Zhixue Zhentong Jiaonang; Primary dysmenorrhea; Clinical efficacy
基金项目
页码 105-105
  • 参考文献
  • 相关文献
  • 引用本文

魏蕾*. 止血镇痛胶囊治疗原发性痛经的临床观察 [J]. 国际医学与数据杂志. 2025; 9; (2). 105 - 105.

  • 文献评论

相关学者

相关机构